Partnered Product Pipeline
Currently, MorphoSys’s partnered product pipeline comprises some 60 antibody programs within its partnerships. MorphoSys’s list of partners includes a roster of blue-chip biotechnology and pharmaceutical firms renowned for their antibody expertise, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co., Novartis, Pfizer and Roche.
Indications of Partnered Programs
Within these partnerships, MorphoSys develops antibodies for the treatment of disease indications such as cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction and inflammation.
MorphoSys Antibodies in Clinical Development
Currently seven HuCAL-based antibody programs are in clinical stage development:
Product candidate and target | Indication | Status | Partner | Additional information |
|---|---|---|---|---|
R1450 | Alzheimer’s disease | P1 | Roche | |
BHQ880 | Oncology | P1/2 | Novartis | |
CNTO888 | Immunology / Oncology | P2 / P2 | Centocor Ortho Biotech | - |
not disclosed | not disclosed | P1 | Novartis | - |
not disclosed | Inflammatory Diseases | P1 | Centocor Ortho Biotech | - |
not disclosed | Oncology | P1 | Bayer Schering Pharma |